EPISODE · Apr 15, 2021 · 2 MIN
Phase 2 UNITY-NHL Study Regarding Umbralisib
from Rare Disease Discussions · host CheckRare Editors
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Embed this episode
NOW PLAYING
Phase 2 UNITY-NHL Study Regarding Umbralisib
No transcript for this episode yet
Similar Episodes
No similar episodes found.